Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression.

Abstract

<h4>Objectives</h4>We aimed to explore the correlation between baseline body mass index (BMI) and the antidepressant properties of intravenous ketamine in patients with depression.<h4>Methods</h4>We divided 135 patients diagnosed with either major depressive disorder (n=103) or bipolar depression (n=32) into lower and higher BMI groups based on their baseline BMI. Patients with a lower BMI (BMI<24 kg/m²; n=92) were included in the lower BMI group, and those with a higher BMI (BMI≥24 kg/m²; n=43) were assigned to the higher BMI group. Each participant received six ketamine infusions. Antidepressant remission was determined using a Montgomery-Åsberg Depression Rating Scale (MADRS; total score of ≤10) within 24 hours after the sixth ketamine infusion on day 13. Antidepressant response was characterized by a ≥50% alleviation in the symptoms of depression at the same time point. Changes in symptoms of depression over time were assessed using a linear mixed model.<h4>Results</h4>The antidepressant response rate in the higher BMI group (67.4%, 95% confidence interval [CI]: 53.5%-81.4%) was higher than that in the lower BMI group (51.1%, 95% CI: 41.3%-60.9%). In addition, the remission rate was higher in the higher BMI group (39.5%, 95% CI: 25.6%-55.8%) than in the lower BMI group (31.5%, 95% CI: 21.7%-41.3%). However, these differences were not significant (all <i>P</i>>0.05). The linear mixed models with covariates indicated a significant group-by-time interaction in the MADRS scores (<i>F</i> _{13, 1729}=3.0, <i>P<</i>0.001). A significant correlation was found between baseline BMI level and the change in depressive symptoms on days 13 and 26 (all <i>P</i><0.05). However, these correlations were not significant after Bonferroni correction or controlling for baseline depressive symptoms (all <i>P</i>>0.05).<h4>Conclusion</h4>Our exploratory, <i>post-hoc</i> analysis of an open-label, single-arm study suggests that patients with depression and a higher baseline BMI may experience greater reductions in depressive symptoms compared with those with a lower baseline BMI after receiving six ketamine infusions.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords